Dirk Laurent

8.2k total citations · 1 hit paper
76 papers, 4.7k citations indexed

About

Dirk Laurent is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Dirk Laurent has authored 76 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Dirk Laurent's work include Colorectal Cancer Treatments and Studies (36 papers), Cancer Treatment and Pharmacology (28 papers) and Angiogenesis and VEGF in Cancer (18 papers). Dirk Laurent is often cited by papers focused on Colorectal Cancer Treatments and Studies (36 papers), Cancer Treatment and Pharmacology (28 papers) and Angiogenesis and VEGF in Cancer (18 papers). Dirk Laurent collaborates with scholars based in Germany, United States and Italy. Dirk Laurent's co-authors include Eric Van Cutsem, Heinz‐Josef Lenz, Salvatore Siena, Daniel J. Sargent, Laurent Mineur, Takayuki Yoshino, Antoine Adenis, Alfredo Falcone, Thierry André and Olivier Bouché and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Dirk Laurent

75 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

2012 2.1k citations Axel Grothey, Eric Van Cutsem et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Laurent Germany	26	3.0k	1.5k	1.5k	975	921	76	4.7k
Allen Lee Cohn United States	38	4.7k 1.6×	1.5k 1.0×	2.4k 1.6×	1.3k 1.3×	1.2k 1.3×	159	6.9k
Mark Kozloff United States	36	3.2k 1.1×	1.3k 0.8×	1.7k 1.1×	702 0.7×	454 0.5×	125	4.7k
Johannes Nippgen Germany	15	3.2k 1.1×	782 0.5×	1.4k 1.0×	629 0.6×	898 1.0×	27	4.3k
Piercarlo Saletti Switzerland	29	4.3k 1.4×	1.0k 0.7×	2.1k 1.4×	1.1k 1.1×	753 0.8×	74	5.5k
Frank Cihon United States	18	2.5k 0.9×	1.1k 0.7×	1.6k 1.1×	654 0.7×	920 1.0×	33	3.8k
Kelly S. Oliner United States	28	4.6k 1.6×	1.3k 0.8×	2.6k 1.7×	1.8k 1.8×	1.3k 1.5×	68	6.4k
Henry Q. Xiong United States	18	2.8k 1.0×	1.2k 0.8×	1.3k 0.9×	1.0k 1.1×	924 1.0×	39	4.3k
Christopher R. Garrett United States	25	2.8k 0.9×	1.4k 0.9×	2.4k 1.6×	780 0.8×	718 0.8×	50	5.3k
Christiane Langer United States	13	4.6k 1.6×	1.1k 0.7×	2.0k 1.3×	1.1k 1.2×	962 1.0×	26	5.8k
M. Mueser France	10	3.8k 1.3×	795 0.5×	1.9k 1.3×	464 0.5×	779 0.8×	18	4.5k

Countries citing papers authored by Dirk Laurent

Since Specialization

Citations

This map shows the geographic impact of Dirk Laurent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Laurent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Laurent more than expected).

Fields of papers citing papers by Dirk Laurent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Laurent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Laurent. The network helps show where Dirk Laurent may publish in the future.

Co-authorship network of co-authors of Dirk Laurent

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Laurent. A scholar is included among the top collaborators of Dirk Laurent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Laurent. Dirk Laurent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merlino, G., Mario Bigioni, Patrizia Tunici, et al.. (2021). 489P MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts. Annals of Oncology. 32. S573–S573. 2 indexed citations

Piccart, Martine, Manuel Ruíz Borrego, H-T. Arkenau, et al.. (2021). 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Annals of Oncology. 32. S478–S479. 4 indexed citations

Piccart, Martine, Manuel Ruíz Borrego, François P. Duhoux, et al.. (2020). 347P Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC). Annals of Oncology. 31. S386–S386. 2 indexed citations

Kim, Sung‐Bae, Funda Meric‐Bernstam, Aparna Kalyan, et al.. (2019). First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Targeted Oncology. 14(5). 591–601. 57 indexed citations

Tabernero, Josep, Heinz‐Josef Lenz, Salvatore Siena, et al.. (2015). Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. The Lancet Oncology. 16(8). 937–948. 228 indexed citations

Grothey, Axel, Alberto Sobrero, Salvatore Siena, et al.. (2013). Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.. Journal of Clinical Oncology. 31(15_suppl). 3637–3637. 27 indexed citations

Grothey, Axel, Eric Van Cutsem, Alberto Sobrero, et al.. (2012). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 381(9863). 303–312. 2053 indexed citations breakdown →

Gauler, Thomas, Benjamin Besse, Audrey Mauguen, et al.. (2011). Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology. 23(3). 678–687. 24 indexed citations

Joensuu, Heikki, Filippo de Braud, Tommaso De Pas, et al.. (2011). Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. British Journal of Cancer. 104(11). 1686–1690. 54 indexed citations

10.

Gauler, Thomas, Benjamin Besse, Jean‐Baptiste Méric, et al.. (2007). C1-01: Phase II open-label study to investigate PTK787/ZK 222584 (PTK/ZK) orally administered as a second-line monotherapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S358–S358. 2 indexed citations

11.

Scott, Edwina N., Gerold Meinhardt, Christian Jacques, Dirk Laurent, & Anne Thomas. (2007). Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opinion on Investigational Drugs. 16(3). 367–379. 78 indexed citations

12.

Thomas, Anne, Tanja Trarbach, Dirk Laurent, et al.. (2007). A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Annals of Oncology. 18(4). 782–788. 40 indexed citations

13.

Giles, Francis J., Alan F. List, Michael P. Carroll, et al.. (2007). PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia Research. 31(7). 891–897. 22 indexed citations

14.

Joensuu, Heikki, Filippo de Braud, Paola Coco, et al.. (2007). Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Annals of Oncology. 19(1). 173–177. 53 indexed citations

15.

Roboz, Gail J., Francis J. Giles, Alan F. List, et al.. (2006). Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 20(6). 952–957. 65 indexed citations

16.

Jost, Lorenz, Hans-Peter Gschwind, T. Jalava, et al.. (2006). Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients. Drug Metabolism and Disposition. 34(11). 1817–1828. 60 indexed citations

17.

Mross, K., Joachim Drevs, Michael Medinger, et al.. (2005). Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. European Journal of Cancer. 41(9). 1291–1299. 129 indexed citations

18.

Drevs, Joachim, Ute Zirrgiebel, K. Mross, et al.. (2005). Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Annals of Oncology. 16(4). 558–565. 95 indexed citations

19.

Hecht, J. Randolph, Tanja Trarbach, E. Jaeger, et al.. (2005). A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Journal of Clinical Oncology. 23(16_suppl). LBA3–LBA3. 161 indexed citations

20.

Laurent, Dirk, Olivier Pradier, Heinz Schmidberger, et al.. (1998). Radiation rendered more cytotoxic by fludarabine monophosphate in a human oropharynx carcinoma cell-line than in fetal lung fibroblasts. Journal of Cancer Research and Clinical Oncology. 124(9). 485–492. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact